Teleflex announced today that Chair, President and CEO Liam Kelly is departing the company, effective immediately.

Wondering if Teleflex is a beaten down medical device stock or a genuine value opportunity at today’s price? Let us unpack what the market is really implying about its future. The share price has ...

Teleflex is selling its acute care, interventional urology, and original equipment manufacturer (OEM) businesses in two separate deals totalling over $2bn as part of the company’s broader portfolio ...

Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak ...

Teleflex is a medical device and instrument manufacturer with $3 billion in sales, supplying a wide range of products. The company saw strong growth in the 2010s as growth slowed down in recent years.

New, independent, publicly traded company (NewCo) consisting of Teleflex’s Urology, Acute Care, and OEM businesses. RemainCo will consist of Teleflex’s Vascular Access, Interventional, and Surgical ...